Tag Archives: Eisai Europe Limited

Life Extending Metastatic Breast Cancer Treatment Halaven(R) (Eribulin) Launches in the United Arab Emirates

HATFIELD, England, April 22, 2015 / PRNewswire — Halaven(R) (eribulin) launches today in the United Arab Emirates (UAE) for the treatment of women with locally advanced or metastatic breast cancer (MBC). Eribulin is a life …

Life-extending Advanced Breast Cancer Treatment Halaven(R) (Eribulin Mesylate) Launched in Kingdom of Saudi Arabia

HATFIELD, England, February 26, 2015 / PRNewswire –

– For EMEA media only: not for Swiss/U.S. Journalists

Innovative breast cancer treatment Halaven(R) (eribulin mesylate) has recently been approved by the Saudi Food and Drug Authority …

Eisai Announces Partnership With Newbridge to Market Breast Cancer Treatment Halaven(R) (Eribulin) Across the Middle East

HATFIELD, England, November 18, 2013/PRNewswire-FirstCall –

Eisai announces today that Halaven(R) (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, …

Eisai Announces Availability of Halaven® (eribulin) in Kuwait

HATFIELD, England, July 29, 2013 / PRNewswire –Partnership deal secured with Yiaco for Kuwait distribution

Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) today announces its partnership with Kuwait’s leading pharmaceutical marketing agency,